Reducing Antibiotic Use for Uncomplicated Urinary Tract Infection in General Practice by Treatment With Uva Ursi (UU)- a Comparative Effectiveness Trial
NCT ID: NCT03151603
Last Updated: 2019-11-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
398 participants
INTERVENTIONAL
2017-05-03
2019-06-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Immediate vs. Conditional Use of Antibiotics in Uncomplicated Urinary Tract Infection (UTI) - ICUTI
NCT01488955
Antibiotic Bladder Instillations vs. Oral Suppression for the Treatment of Recurrent Urinary Tract Infections
NCT04285320
A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI)
NCT04020341
Can Consumption of an Aronia-mixture Prevent Urinary Tract Infections in Female Patients?
NCT06618768
Clinical Effectiveness and Bacteriological Eradication of 4 Short-course Antibiotics for Uncomplicated UTIs in Women.
NCT04959331
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Uva Ursi
placebo to fosfomycin: 3 g granules orally 1x1 (day 0)
and
Uva Ursi: 105 mg (Arctuvan®) 3x2 tablets orally from day 0 for 5 days
Arctuvan
application of a herbal drug
Placebo to Fosfomycin
application of Placebo to Fosfomycin
fosfomycin
fosfomycin (Monuril®): 3 g granules orally 1x1 (day 0),
and
placebo to Uva Ursi: 3x2 tablets orally from day 0 for 5 days
If the patient returns with persistent/recurrent symptoms, antibiotic therapy according to the sensitivity test.
Fosfomycin
application of an antibiotic drug
Placebo to Arctuvan
application of Placebo to Arctuvan
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Arctuvan
application of a herbal drug
Fosfomycin
application of an antibiotic drug
Placebo to Arctuvan
application of Placebo to Arctuvan
Placebo to Fosfomycin
application of Placebo to Fosfomycin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* at least two symptoms of UTI (dysuria, urgency of micturition, frequency, lower abdominal pain)
* Written informed consent
Exclusion Criteria
* conditions that may lead to complicated infections (i.e. renal diseases, patients with urinary catheter)
* pregnancy/ breastfeeding
* current self-medication with UU preparations e.g. z.B. Cystinol®, Uvalysat®, Arctuvan®
* antibiotic use in the last 7 days
* previous UTI in the past 2 weeks
* history of pyelonephritis
* contraindications for trial drugs
* serious diseases
* inability to understand trial Information
* current participation in another clinical trial or participation in another clinical trial within the last 4 weeks
18 Years
75 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Medical Center Goettingen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Karsten Gavenis
Quality Assurance Staff Unit Clinical Trials
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eva Hummers-Pradier, Prof. Dr.
Role: PRINCIPAL_INVESTIGATOR
University Medical Center Göttingen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hausarztpraxis Dr. Raby
Achim, , Germany
General Practice Aden
Braunschweig, , Germany
General Practice Scheffer
Braunschweig, , Germany
General Practice Coutelle
Bremen, , Germany
General Practice Schelp
Bremen, , Germany
General Practice Dickow
Burgwedel, , Germany
General Practice Kiwit-Putzer
Burgwedel, , Germany
Praxis Zietz
Celle, , Germany
General Practice Kutzsche
Emmerthal, , Germany
Praxis Dr. Bahr
Gieboldehausen, , Germany
General Practice Müller
Gillersheim, , Germany
Institute of General Medicine, University Medical Center Goettingen
Göttingen, , Germany
Praxisgemeinschaft Jacob / Kling
Göttingen, , Germany
General Practice Keske
Göttingen, , Germany
General Practice Koch
Göttingen, , Germany
General Practice Kolb
Göttingen, , Germany
General Practice Lang
Göttingen, , Germany
General Practice Lückerath
Göttingen, , Germany
Praxis Dr. Egner
Hanover, , Germany
Institute of General Medicine, MHH Hannover
Hanover, , Germany
General Practice Barth
Hanover, , Germany
General Practice Löber
Hardegsen, , Germany
Gemeinschaftspraxis Dres Schlesier / Eckhardt
Heilbad Heiligenstadt, , Germany
Gemeinschaftspraxis Hartleb / Stöcking
Heilbad Heiligenstadt, , Germany
Praxis Dr. Koch
Heilbad Heiligenstadt, , Germany
Praxisgemeinschaft Seitz / Eckert
Herzberg, , Germany
General Practice Wilde
Hildesheim, , Germany
Praxisgemeinschaft Stoltz / Raddatz
Höxter, , Germany
General Practice Beverungen
Höxter, , Germany
Gemeinschaftspraxis Kasperczyk / Schindewolf-Lensch
Isernhagen-Süd, , Germany
General Practice Franz
Katlenburg-Lindau, , Germany
Praxis Dr. Ohlendorf
Langenhagen, , Germany
General Practice Ertel
Langwedel, , Germany
General Practice Wehrbein
Lemförde, , Germany
General Practice Lindenblatt
Neustadt, , Germany
Hausarztzentrum Nörten
Nörten-Hardenberg, , Germany
General Practice Preiskorn
Rehburg-Loccum, , Germany
General Practice Meier-Ahrens
Rosdorf, , Germany
General Practice Woitschek
Salzgitter, , Germany
General Practice Beulshausen
Sattenhausen, , Germany
General Practice Schulte
Scheeßel, , Germany
General Practice Böttcher
Schwanewede, , Germany
General Practice Albrecht
Springe, , Germany
General Practice Wolf
Uslar, , Germany
General Practice Schmiemann
Verden an der Aller, , Germany
General Practice Annweiler
Waake, , Germany
General Practice Stegemann
Wunstorf, , Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gagyor I, Hummers E, Schmiemann G, Friede T, Pfeiffer S, Afshar K, Bleidorn J. Herbal treatment with uva ursi extract versus fosfomycin in women with uncomplicated urinary tract infection in primary care: a randomized controlled trial. Clin Microbiol Infect. 2021 Oct;27(10):1441-1447. doi: 10.1016/j.cmi.2021.05.032. Epub 2021 Jun 7.
Afshar K, Fleischmann N, Schmiemann G, Bleidorn J, Hummers-Pradier E, Friede T, Wegscheider K, Moore M, Gagyor I. Reducing antibiotic use for uncomplicated urinary tract infection in general practice by treatment with uva-ursi (REGATTA) - a double-blind, randomized, controlled comparative effectiveness trial. BMC Complement Altern Med. 2018 Jul 3;18(1):203. doi: 10.1186/s12906-018-2266-x.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
01579
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.